Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I–II trial
Willemien J. van Driel(The Netherlands Cancer Institute), J. Baptist Trimbos(Leiden University), Rienk Offringa(German Cancer Research Center), Remco M.P. Brandt(Leiden University), Gert Jan Fleuren(Leiden University Medical Center), Ed Schuuring(University Medical Center Groningen), Thomas Bauknecht(University of Freiburg), W. Martin Kast(University of Southern California), Maaike E. Ressing(Utrecht University), A.B. van Rossum(Leiden University), Gemma G. Kenter(European Organisation for Research and Treatment of Cancer), A. Tamm-Hermelink(University of Freiburg), C J Melief(Leiden University), E. J. T. Krul(Leiden University), Peter A. van Dam(University of Antwerp)
Cited by 230
Related Papers
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840